|Printable version||E-mail this to a friend|
How to facilitate development of cancer treatment based on genetically modified T-cells
Watch live broadcast of expert discussion at EMA
A workshop on the scientific and regulatory challenges of innovative cancer immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and bacteria) will take place at the European Medicines Agency (EMA) on Tuesday and Wednesday, 15-16 November 2016.
You can follow a live broadcast of the workshop by clicking on the 'multimedia' tab on the event page.
The workshop, which is organised by the Agency’s Committee for Advanced Therapies(CAT), aims to facilitate dialogue between the CAT and medicine developers from industry and academia on current scientific developments, regulatory requirements for product manufacture and clinical development of these medicines.
Immunotherapy is a type of cancer treatment that mobilises the body's own defence mechanisms to fight the cancer. Immunotherapy medicines have significantly improved the therapeutic landscape for patients with certain cancers, such as lung cancer or melanoma.
T-cell based immunotherapy is an innovative approach where T-cells from a patient’s blood are genetically engineered in a laboratory to allow them to recognise cancer cells through specific receptor proteins. In the body of a patient, these so called Chimeric Antigen Receptor (CAR) T-cells can then identify and destroy cancer cells.
CAR T-cell medicines are being developed and are currently being tested in clinical trialsin a variety of cancers. However, there are still many scientific and regulatory challenges to be overcome before these innovative products can be brought to the market for the benefit of patients.
For more information please see the agenda of the workshop.
Presentations and a video recording of the event will be published after the workshop.
- Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (15-16/11/2016)
- Committee for Advanced Therapies (CAT)
- Programme of the Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (08/11/2016)
Latest News from
How certain are you? Help us to better explain scientific uncertainty25/02/2017 08:10:00
Can you help us? We are running a survey to help us improve how EFSA communicates and explains the scientific uncertainties related to its assessments. The survey is being jointly run with our partners in eight EU Member States: Cyprus, France, Germany, Greece, Ireland, Romania, Spain and the UK.
Only a strong economy can allow Europe to weather the storm24/02/2017 16:10:00
EESC proposes fostering economic growth and "beyond-GDP" indicators.
EU must take lead in linking trade in agriculture with the SDGs24/02/2017 14:05:00
Time to breathe new life into the WTO process. Trade in agriculture and in agricultural products has never been so important – or so controversial.
Local leaders urge concerted international action to stabilise Mediterranean24/02/2017 12:20:00
Local and regional leaders from across the Mediterranean and the European Union have urged national governments and the international community to work more closely with mayors and governors to help stabilise North Africa and the Middle East.